May 25, 2024
Loading...
You are here:  Home  >  'Atara Biotherapeutics'  -  Page 2
Latest

Atara reports patient death in cancer treatment study

By   /  Tuesday, February 22nd, 2022  /  Banking & Finance, Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Atara reports patient death in cancer treatment study

Atara Biotherapeutics, a South San Francisco-based drug development company with major operations in Thousand Oaks, reported to the U.S. Food and Drug Administration on Feb. 18 that a patient died in one of its Phase 1 trials. The patient, who was being treated at a Memorial Sloan Kettering Cancer Center location in New York, suffered Read More →

Latest

Atara reports growing losses, but plenty of cash left

By   /  Friday, November 5th, 2021  /  Banking & Finance, Earnings, East Ventura County, Health Care & Life Science, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Atara reports growing losses, but plenty of cash left

Atara Biotherapeutics continued seeing losses in the third quarter of fiscal year 2021, but has enough cash on hand to remain solvent as it awaits news on its tab-cel therapy treatment in early 2022. Atara, a South San Francisco-based immunotherapy based company with major operations in Westlake Village, reported net losses of $84.7 million in Read More →

Latest

Atara losses grew in Q2

By   /  Monday, August 9th, 2021  /  Banking & Finance, Earnings, East Ventura County, Health Care & Life Science, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Atara losses grew in Q2

Atara Biotherapeutics swallowed more losses in the second quarter of 2021, as the early-stage company hopes for good news for its tab-cel therapy in early 2022. Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Oaks, had a net loss of $83.7 million in the second Read More →

Latest

Atara beats estimates with loss in Q1

By   /  Tuesday, May 4th, 2021  /  Banking & Finance, Earnings, East Ventura County, Health Care & Life Science, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Atara beats estimates with loss in Q1

Atara Biotherapeutics had a net loss of $78.2 million in the first quarter of fiscal year 2021, slightly higher compared than same quarter a year earlier, when the company had a loss of $73.5 million. Despite this, Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Read More →

Latest

Amgen CEO again tops list of region’s highest paid execs

By   /  Friday, April 30th, 2021  /  Banking & Finance, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen CEO again tops list of region’s highest paid execs

Robert Bradway remained the highest paid executive in the Tri-Counties in 2020, but stock options and new faces changed a lot of the names and positions on the list. Bradway, the CEO of Amgen, earned $20.13 million in total compensation in 2020 — 3% more than he earned in 2019, and 8.23% more than in Read More →

Latest

Making an ImmPACT: New firm raises $18M to pursue T-cell therapies

By   /  Friday, August 28th, 2020  /  Health Care & Life Science, Latest news  /  Comments Off on Making an ImmPACT: New firm raises $18M to pursue T-cell therapies

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Atara Biotherapeutics raises $175 million

By   /  Friday, June 5th, 2020  /  East Ventura County, Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Atara Biotherapeutics raises $175 million

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.